Clinical Trial Search

Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters

Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants

Primary: Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. — 12.2 Change in ETDRS Letters — p=0.0015

Primary: Change in Excess Central Macular Thickening in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline — -38.60 µm

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline — 10.6; 7.8; 13.1; 9.4 letters

Primary: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks — 45; 10 Participants — p=<0.001

Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…

Primary: Proportion of Baseline Central Subfield Thickness Observed at 8 Weeks — .77; .61; .54 proportion of baseline retinal thickness — p=<0.0001

Primary: Change From Baseline in Central Subfield Thickness, Measured Using Optical Coherence Tomography, After Treatment With CLS-TA in Subjects With Macular Edema Following…

Primary: Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis — 6.0; 3.2…

Primary: Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 12 Months — 413.4 Microns

Primary: Proportion of Baseline Central Subfield Thickness Observed at 12 Weeks — 0.65; 0.88; 0.79 Proportion of baseline retinal thickness — p=<0.001

Primary: Adverse Events — 27; 1 Participants

Primary: The Change in Visual Acuity (Number of ETDRS Letters). — 67.8; 71.9; 69.6; 72.9 ETDRS letters

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts — 12.5; 14; 13.5 letters read correctly

Primary: Number of Participants With Systemic Toxicities, Adverse Events, or Infections — 6 Participants

Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants

Primary: The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5 — 28; 44; 27 Participants

Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters

Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters

Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 53; 48; 38 Number of Participants

Primary: Cumulative Response Rate of 15 or More Letter Improvement — 0.101; 0.092; 0.045; 0.258 Kaplan-Meier Estimate

Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters

Primary: Macular Thickness at 3 Days After Intravitreous Dexamethasone — 438.44; 465.22; 368.22 µm

Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants

Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns

Primary: Number of Participants With Absence of Intraocular Inflammation at 6 Months — 12 Participants

Primary: Frequency of Ocular Adverse Events, Systemic Adverse Events, Serious, and Treatment-emergent Non-serious Adverse Events — 10; 8; 3; 5 Participants